UBT251 is a triple agonist of the receptors for GLP-1, GIP and glucagon (triple G), being jointly developed by United Biotechnology and Novo Nordisk In a placebo-controlled phase 2 trial in Chinese people with overweight or obesity, UBT251 led to a statistically significant mean weight loss of up to 19.7% after 24 weeks UBT251 appeared to have a safe and well-tolerated profile consistent with... slovenia times več »
Več iz medija
Slovenian engineer picked to design major new bridge in...
slovenia times več »
Triple agonist UBT251 delivers up to 19.7% mean weight loss after 24 weeks in...
UBT251 is a triple agonist of the receptors for GLP-1, GIP and glucagon (triple G), being jointly developed by United Biotechnology and Novo Nordisk In a... slovenia times več »
Story of post-WWII exodus brought to screen
A new historical drama depicting events in early May 1945 when opponents of the communist regime fled Yugoslavia toward Allied-controlled Austrian Carinthia is... slovenia times več »
The Slovenia Times
Gathering Global Experts Delivering Insights from the forefront of Space Science and Sustainability slovenia times več »
Banyan Group Residences Introduces Angsana Golf Residences Topaz at Laguna...
slovenia times več »
Nika Prevc claims Olympic bronze to achieve sweep in Milano...
slovenia times več »
Spring Fair at VEC Marks Vietnams Most Ambitious Showcase...
For 12 days, the Spring Fair transformed VEC into a walkable map of 34 provinces, blending cuisine, culture and commerce inside Southeast Asia's largest... slovenia times več »
HKCERT Capture The Flag Challenge 2025 Achieves a Record 40% Surge in...
First-Ever Attack-Defence Simulation Aligns with Real Corporate Needs Setting a New Benchmark for Local Cybersecurity Competitions slovenia times več »